<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="no drugs are validated to have significant efficacy in clinical" exact="treatment" post="of COVID-19 patients in large-scale studies. Remdesivir is considered"/>
 <result pre="exposure in cytoplasm) and monoclonal and polyclonal antibodies in the" exact="treatment" post="of SARS-CoV-2 are under investigation. Avoiding the prescription of"/>
 <result pre="Nevertheless, contrary to the SARS cases in 2003,10 some SARS-CoV-2" exact="infection" post="patients did not have the prodromal symptoms of upper"/>
 <result pre="did not have the prodromal symptoms of upper respiratory tract" exact="infection" post="(e.g., cough, sore throat, rhinorrhea), viremia-associated laboratory abnormalities (e.g.,"/>
 <result pre="In addition, uncertain seasonality and the incubation period of SARS-CoV-2" exact="infection" post="oscillating between 2 and 14 days make it remarkably"/>
 <result pre="and 14 days make it remarkably difficult to achieve early" exact="diagnosis" post="and initiate treatment on time.5,9 Previous studies demonstrated that"/>
 <result pre="make it remarkably difficult to achieve early diagnosis and initiate" exact="treatment" post="on time.5,9 Previous studies demonstrated that human coronavirus-NL63 (HCoV-NL63)"/>
 <result pre="children are considered to be significantly less susceptible to HCoV-NL63" exact="infection" post="and have milder disease severity than adults,1,5,8,13 the SARS-CoV-2"/>
 <result pre="infection and have milder disease severity than adults,1,5,8,13 the SARS-CoV-2" exact="infection" post="has become a public health menace to people around"/>
 <result pre="In order to contain SARS-CoV-2 spread among community residents, stringent" exact="infection" post="control measures were implemented by the Centers for Disease"/>
 <result pre="an investigation by To et al. (2020),15 patients with SARS-CoV" exact="infection" post="had the highest viral load (measured from posterior oropharyngeal"/>
 <result pre="agents might be beneficial in controlling COVID-19 severity.15 However, standard" exact="treatment" post="against COVID-19 is presently lacking. Herein, the roles of"/>
 <result pre="inhibitors Remdesivir Among several potential drugs tested for efficacy in" exact="treatment" post="of SARS-CoV-2 infection,16 remdesivir (GS-5734; Gilead Sciences Inc., Foster"/>
 <result pre="at least 24 h,20 supporting its clinical potential in the" exact="treatment" post="of human SARS-CoV-2 infection. Additionally, data on the safety"/>
 <result pre="been initiated to evaluate its efficacy in patients with SARS-CoV-2" exact="infection" post="since March, 2020. Patients received 200 mg on day"/>
 <result pre="in vitro potency against SARS-CoV-2 and the clinical success in" exact="treatment" post="of COVID-19,4,18 uncertainties about adverse effects (e.g., nausea, vomiting,"/>
 <result pre="Of note, the similar efficacy of prophylactic and therapeutic remdesivir" exact="treatment" post="(24 h prior to inoculation, and 12 h post-inoculation,"/>
 <result pre="clinical studies have shown favipiravir to have promising potency in" exact="treatment" post="of Chinese patients with SARS-CoV-2 infection.28 Favipiravir was approved"/>
 <result pre="Chinese patients with SARS-CoV-2 infection.28 Favipiravir was approved for the" exact="treatment" post="of COVID-19 in China in March, 2020. In addition,"/>
 <result pre="in China in March, 2020. In addition, patients with COVID-19" exact="infection" post="are being recruited for randomized trials to evaluate the"/>
 <result pre="Lopinavir/ritonavir Protease inhibitors (PIs) are important agents in the contemporary" exact="treatment" post="of patients with chronic human immunodeficiency virus (HIV) infection."/>
 <result pre="LPV's half-life)-IFNb combination therapy in a humanized transgenic mouse MERS-CoV" exact="infection" post="model. They observed the efficacy of remdesivir was superior"/>
 <result pre="and diarrhea) induced by LPV/RTV, it is noteworthy that LPV/RTV" exact="treatment" post="alone (400/100 mg administered orally twice daily for 14"/>
 <result pre="the group receiving LPV/RTV in the late stage of SARS-CoV-2" exact="infection" post="compared with the standard-care group. Moreover, Baden and Ruben"/>
 <result pre="was recently reported as a potential broad-spectrum antiviral drug for" exact="treatment" post="of viruses such as influenza H5N1 in an animal"/>
 <result pre="infected by SARS-CoV-2), an extensive prescription of chloroquine in clinical" exact="treatment" post="of SARS-CoV-2 is a completely off-label use. It is"/>
 <result pre="mg three times per day for 10 days) in the" exact="treatment" post="of 20 patients with severe COVID-19. Mean serum hydroxychloroquine"/>
 <result pre="azithromycin might be a promising alternative to remdesivir in the" exact="treatment" post="of patients with SARS-CoV-2 infection in the future. Nevertheless,"/>
 <result pre="alternative to remdesivir in the treatment of patients with SARS-CoV-2" exact="infection" post="in the future. Nevertheless, the possibility of complicated QTc"/>
 <result pre=". Table 1 Mechanisms of action and targets of potential" exact="treatment" post="agents for SARS-CoV-2 infections. Table 1 Mechanism of action"/>
 <result pre="Switzerland) is a monoclonal antibody that is used in the" exact="treatment" post="of RA exacerbation. It was designed to inhibit the"/>
 <result pre="cytokine release syndrome. Currently, it is also being investigated for" exact="treatment" post="of COVID-19.54 Convalescent plasma Convalescent plasma has also been"/>
 <result pre="immunoglobulin antibodies in the plasma of patients recovering from viral" exact="infection" post="might suppress viremia. Shen et al. (2020) reported on"/>
 <result pre="for these treatments in the prevention of this emerging viral" exact="infection" post="is lacking.57,58 During the COVID-19 outbreak in China, some"/>
 <result pre="effect of Chinese medicine.57,58 Antimicrobial agents for potential co-infection The" exact="prevalence" post="of co-infection varied among COVID-19 patients, ranging from 0%"/>
 <result pre="of an ACE inhibitor or ARB for patients with SARS-CoV" exact="infection" post="in the absence of ARDS is advised. Additionally, despite"/>
 <result pre="note, according to a study by Wu et al. (2020)," exact="treatment" post="of COVID-19 patients with methylprednisolone was shown to decrease"/>
 <result pre="reduced severity of ARDS among patients with lower respiratory tract" exact="infection" post="caused by RSV.70 Fedson et al. (2016, 2020) observed"/>
 <result pre="(2016, 2020) observed that statins target the host response to" exact="infection" post="(endothelial dysfunction) rather than the virus itself, and suggested"/>
 <result pre="treat critically ill patients. Most of the potential drugs for" exact="treatment" post="of COVID-19 are being investigated for safety and efficacy"/>
 <result pre="with hydroxychloroquine plus azithromycin appear to be acceptable alternatives for" exact="treatment" post="of COVID-19 patients. For patients with SARS-CoV-2 infection, ACE"/>
 <result pre="COVID-19 patients. Finally, low-dose steroid (hydrocortisone) might be prescribed for" exact="treatment" post="of refractory shock in patients with COVID-19. Funding No"/>
 <result pre="patients with 2019 novel coronavirus in the early stagemedRxiv202010.1101/2020.02.10.20021584 9CaoQ.ChenY.C.ChenC.L.ChiuC.H.SARS-CoV-2" exact="infection" post="in children: transmission dynamics and clinical characteristicsJ Formos Med"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect Dis2020 Mar"/>
 <result pre="Antimicrob Agents2020 Mar 610593310.1016/j.ijantimicag.2020.10593332147516 25de WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
 <result pre="Fromhttp://www.xinhuanet.com/english/2020-03/17/c_138888226.htm 29ChanJ.F.W.YaoY.YeungM.L.DengW.BaoL.JiaL.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 <result pre="in MERS-CoV-infected rhesus macaquesNat Med1920131313131724013700 36ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225614985565 37YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res23201330030223208422 38VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent"/>
 <result pre="modelCell Res23201330030223208422 38VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056910.1186/1743-422X-2-6916115318 39WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="review on the efficacy and safety of chloroquine for the" exact="treatment" post="of COVID-19J Crit Care2020 Mar 1010.1016/j.jcrc.2020.03.005pii: S0883-9441(20)30390-7 41YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.In vitro"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
 <result pre="Infect Dis2020 Mar 910.1093/cid/ciaa237pii: S1684-1182 42GautretP.LagierJ.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
 <result pre="such illnesses: a randomized clinical trialJAMA31420152034204426575060 45WangY.CuiR.LiG.GaoQ.YuanS.AltmeyerR.Teicoplanin inhibits Ebola pseudovirus" exact="infection" post="in cell cultureAntivir Res12520161710.1016/j.antiviral.2015.11.00326585243 46ZhouN.PanT.ZhangJ.LiQ.ZhangX.BaiC.Glycopeptide antibiotics potently inhibit cathepsin"/>
 <result pre="coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 47BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.M.Teicoplanin: an alternative drug for the" exact="treatment" post="of coronavirus COVID-19?Int J Antimicrob Agents2020 Mar 1310594410.1016/j.ijantimicag.2020.10594432179150 48BeigelJ.H.NamH.H.AdamsP.L.KrafftA.InceW.L.El-KamaryS.S.Advances"/>
 <result pre="control by the humoral immune responseJ Virol8520114122413421325420 52KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
 <result pre="among patients with COVID-19.(manuscript submitted). 60ChouC.C.ShenC.F.ChenS.J.ChenH.M.WangY.C.ChangW.S.Recommendations and guidelines for the" exact="treatment" post="of pneumonia in TaiwanJ Microbiol Immunol Infect52201917219910.1016/j.jmii.2018.11.00430612923 61JeanS.S.ChangY.C.LinW.C.LeeW.S.HsuehP.R.HsuC.W.Epidemiology, treatment,"/>
 <result pre="2019 pneumonia in Wuhan, ChinaJAMA Intern Med2020 Mar 1310.1001/jamainternmed.2020.0994 69TangN.BaiH.ChenX.GongJ.LiD.SunZ.Anticoagulant" exact="treatment" post="is associated with decreased mortality in severe coronavirus disease"/>
</results>
